Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Cash Burn ⢠Heavy Losses NRIX's strong liquidity and low leverage provide near-term flexibility, but persistent losses, heavy cash burn, declining equity, and elevated valuation make the shares high risk.
Price Behavior
Key Price Behavior Insights: ⢠Bearish trend ⢠Support holding ⢠$26.30 breakout Support Level: $24.83â$25.10 Resistance Level: $26.20â$26.30 NRIX remains bearish over the last month but is stabilizing above $24.83â$25.10 support; watch for a recovery above $26.30 to improve momentum or a break below $24.83 for further downside.
Sentiment & News
Key News Insights: ⢠Roche Funding ⢠Phase 3 Plans ⢠Analyst Upgrade Nurix gains momentum from Roche's $700M partnership, promising bexobrutideg trial data, and improved investor sentiment.
AI Summary
NRIX is now a better-funded but more binary clinical investment: Roche's $700M upfront payment, global-development support, and 50% U.S. profit share strengthen upside and reduce dilution risk, but the $2.56B valuation hinges on bexobrutideg proving superiority to pirtobrutinib in Phase 3 CLL/SLL. Investors should view the shares as catalyst-driven exposureâconstructive above ~$24.83 support, but vulnerable to pivotal-trial, safety, or enrollment setbacks.
Description
Nurix Therapeutics is a biopharmaceutical company that discovers and develops small-molecule treatments for oncology and immune disorders, with an emphasis on orally administered BTK degraders and CBLâB modulators. Its pipeline includes agents for relapsed or refractory Bâcell malignancies, therapies to support adoptive Tâcell approaches, and a cell therapy candidate in Phase 1 for gynecologic cancers. The company collaborates with Gilead and Sanofi, was incorporated in 2009, and is headquartered in San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 15 | Jul 22 | NRIX | Nurix Therapeutics, Inc. | Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape. | Closed | -1.1% |
| Jul 2 | Jul 9 | NRIX | Nurix Therapeutics, Inc. | Strong near-term catalyst and momentum setup: stock rose about 42% over 21 trading days, supported by Roche collaboration worth up to $2.3B with $700M upfront and positive NX-5948 CLL/SLL data including 92.9% ORR in a second-line group. | Closed | +3.0% |